A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502446-27-00

Acronym

64407564MMY3009

Enrollment

453

Registered

2024-02-13

Start date

2024-02-26

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Myeloma

Brief summary

Progression-Free Survival

Interventions

DRUGEmpliciti 400 mg powder for concentrate for solution for infusion.

DRUGteclistamab

DRUGDexamethasone Tablets BP 2.0mg

DRUGVELCADE 3.5 mg powder for solution for injection

DRUGJNJ-64407564

DRUGDexamethason 8 mg GALEN® Tabletten

DRUGImnovid 2 mg hard capsules

DRUGImnovid 3 mg hard capsules

DRUGPomalidomide

DRUGPrivigen 100 mg/ml solution for infusion

DRUGImnovid 1 mg hard capsules

DRUGEmpliciti 300 mg powder for concentrate for solution for infusion.

DRUGDexamethason 4 mg JENAPHARM®

DRUGImnovid 4 mg hard capsules

DRUGFortecortin® 2 mg Tabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026